Explorer les evidences

11 %Clade G accounted for 11% of the studied HIV infections in Cameroonian blood donors.

CamerounVIH/sidapublié 2013Virology JournalOpenAlexdocument de 7 observationsDOI 10.1186/1743-422x-10-29

60 %Sixty percent of the 142 strains had one mutation in the protease gene.

CamerounVIH/sidapublié 2000Journal of Clinical MicrobiologyOpenAlexdocument de 19 observations

1 070 SFU/10^6 PBMCThe median T cell response to Nef was 1070 spot forming units per 10^6 PBMC.

CamerounVIH/sidapublié 2009RetrovirologyOpenAlexdocument de 6 observationsDOI 10.1186/1742-4690-6-s3-p273

5,3 %Among ART initiators with no prior exposure to antiretrovirals in rural areas of Cameroon, pretreatment HIV drug resistance (PDR) prevalence was 5.3% (95% CI 1.4%–17.5%).

CamerounVIH/sidaobservé 2015publié 2018Journal of Antimicrobial ChemotherapyOpenAlexdocument de 12 observationsDOI 10.1093/jac/dky221

106 cells_per_mm3CD4 count increased by a median of 106 cells/mm3 at 12 months.

CamerounVIH/sidaobservé 12 monthspublié 2005Antiviral TherapyOpenAlexdocument de 8 observationsDOI 10.1177/135965350501000208

7,4 %HIV seroprevalence in a general population of southern Cameroon is 7.4%.

CamerounVIH/sidapublié 2007Emerging infectious diseasesOpenAlexdocument de 7 observationsDOI 10.3201/eid1303.061069

1 specimensPhylogenetic analysis of the gp41 region of 123 HIV-1-seropositive specimens from Cameroon showed that 1 was subtype H.

CamerounVIH/sidapublié 2000AIDS Research and Human RetrovirusesOpenAlexdocument de 7 observations

9 %Nine percent of HIV sequences (29/321) were from participants reporting previous exposure to antiretrovirals.

CamerounVIH/sidaobservé 2015publié 2018The Journal of antimicrobial chemotherapyeurope_pmcdocument de 12 observationsDOI 10.1093/jac/dky221

50 %Circulating recombinant form CRF02_AG accounted for 50% of the studied HIV infections in Cameroonian blood donors.

CamerounVIH/sidapublié 2013Virology JournalOpenAlexdocument de 7 observationsDOI 10.1186/1743-422x-10-29

98 %The prevalence of the 89M/I substitution in protease sequences was 98% (56/57) among 57 HIV-1-infected treatment-naive individuals from Cameroon.

CamerounVIH/sidapublié 2011AIDS Research and Human RetrovirusesOpenAlexdocument de 24 observations

13,5 %Among ART initiators with no prior exposure to antiretrovirals in urban areas of Cameroon, pretreatment HIV drug resistance (PDR) prevalence was 13.5% (95% CI 5.1%–31.5%).

CamerounVIH/sidaobservé 2015publié 2018Journal of Antimicrobial ChemotherapyOpenAlexdocument de 12 observationsDOI 10.1093/jac/dky221

3,3 %The overall early vertical transmission rate of HIV among 1827 tested infants was 3.3% (95% CI 2.5–4.3).

CamerounVIH/sidaobservé November 2007 to October 2010publié 2019Paediatrics and international child healthPubMeddocument de 7 observations

98,7 %371 out of 376 patients (98.7%) started on a first-line antiretroviral regimen that included 3TC + d4T/AZT + NVP/EFV in Cameroon.

CamerounVIH/sidapublié 2013Journal of the International AIDS Societyeurope_pmcdocument de 4 observations

4,43 aORVirologic failure was associated with the nevirapine concentration with an adjusted odds ratio of 4.43.

CamerounVIH/sidapublié 2008Journal of acquired immune deficiency syndromes (1999)europe_pmcdocument de 11 observationsDOI 10.1097/qai.0b013e3181743955

89 %The prevalence of the 20I/R substitution in protease sequences was 89% (51/57) among 57 HIV-1-infected treatment-naive individuals from Cameroon.

CamerounVIH/sidapublié 2011AIDS Research and Human RetrovirusesOpenAlexdocument de 24 observations

45 %In 2010, 45% of 38 ART sites in Cameroon attained the target for ARV drug supply continuity (target = 100%).

CamerounVIH/sidaobservé 2010publié 2012PLoS ONEOpenAlexdocument de 5 observationsDOI 10.1371/journal.pone.0036777

7,8 %179 adults (7.8%) tested HIV-positive in the campaign.

CamerounVIH/sidaobservé 2011publié 2012Journal of the International AIDS Societyeurope_pmcdocument de 39 observations

7,4 %The overall HIV seroprevalence rate in the study population was 7.4% (95% CI 5.2%–10.1%).

CamerounVIH/sidaobservé 2001publié 2007Emerging infectious diseasesOpenAlexdocument de 7 observationsDOI 10.3201/eid1303.061069

1 776 adolescentsBetween 2004 and 2010, 1,776 adolescents commenced antiretroviral therapy (ART) at Mpilo OI ART clinic, Bulawayo.

CamerounVIH/sidaobservé 2004 to 2010publié 2012Journal of the International AIDS Societyeurope_pmcdocument de 39 observations

20,5 %Among 458 patients who initiated antiretroviral therapy in rural district hospitals in Cameroon between 2006 and 2008, 94 (20.5%) classified at WHO clinical stage 3 had a CD4 count above 350 cells/mm³.

CamerounVIH/sidaobservé 2006-2008publié 2010Tropical medicine & international health : TM & IHeurope_pmcdocument de 7 observations

0,7 %The M46I mutation was identified in 0.7% of the 142 HIV-1 isolates in the protease gene.

CamerounVIH/sidapublié 2000Journal of Clinical MicrobiologyOpenAlexdocument de 19 observations

5 %The prevalence of the 62V substitution in protease sequences was 5% (3/57) among 57 HIV-1-infected treatment-naive individuals from Cameroon.

CamerounVIH/sidapublié 2011AIDS Research and Human RetrovirusesOpenAlexdocument de 24 observations

86,9 %86.9% of the intention-to-treat population had viral load <400 copies/ml at 12 months.

CamerounVIH/sidaobservé 12 monthspublié 2005Antiviral TherapyOpenAlexdocument de 8 observationsDOI 10.1177/135965350501000208

9 360 adultsBetween 2004 and 2010, 9,360 adults commenced antiretroviral therapy (ART) at Mpilo OI ART clinic, Bulawayo.

CamerounVIH/sidaobservé 2004 to 2010publié 2012Journal of the International AIDS Societyeurope_pmcdocument de 39 observations

The prevalence of hypercholesterolaemia was significantly increased with duration of highly active antiretroviral therapy (HAART) in HIV-infected Cameroonians.

CamerounVIH/sidapublié 2013Diabetes & metabolismeurope_pmcdocument de 12 observations